How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,541 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

11461. Knowledge and use of secondary contraception among patients requesting termination of pregnancy. Full Text available with Trip Pro

no medical advice. There was a range of knowledge of postcoital contraceptive methods. Knowledge of how to deal with forgotten pills, severe vomiting, severe diarrhea, and concurrent antibiotic treatment among the 422 patients who had ever used the combined pill also was variable. 19% of the 372 patients treated by general practitioners knew 4 correct answers, but 50% of the 50 patients in community family planning clinics answered correctly 4 times. Differences could not be explained by other (...) Knowledge and use of secondary contraception among patients requesting termination of pregnancy. 8461770 1993 05 05 2008 11 20 0959-8138 306 6877 1993 Feb 27 BMJ (Clinical research ed.) BMJ Knowledge and use of secondary contraception among patients requesting termination of pregnancy. 556-7 Bromham D R DR Fertility Control Unit, St James's University Hospital, Leeds. Cartmill R S RS eng Journal Article England BMJ 8900488 0959-8138 0 Contraceptives, Postcoital AIM IM J BMJ. 1993 Apr 3;306(6882

1993 BMJ : British Medical Journal

11462. Seven days of ceftriaxone therapy is as effective as ten days' treatment for bacterial meningitis. (Abstract)

received seven days of therapy compared with patients treated for the conventional ten days. Diarrhea occurred in 44% of those receiving the drug. Patients treated with the seven-day regimen were discharged from the hospital approximately two days earlier than those with the ten-day regimen. (...) of therapy. The population characteristics and etiologic agents were similar for the two treatment groups, as were also the findings on examination and culture of cerebrospinal fluid at completion of therapy. There were no significant differences in the frequency and types of neurological complications between the two treatment groups; four patients in each group had two or more neurological abnormalities. The rates of nosocomial infections and prolonged and secondary fever were similar in those who

1985 JAMA Controlled trial quality: uncertain

11463. Vancomycin vs. Metronidazole in C. difficile Diarrhea: Vancomycin vs. metronidazole in C. difficile

Question In patients with Clostridium difficile -associated diarrhea, how does metronidazole compare with vancomycin in regards to effecting a cure and preventing relapse? Bottom Line Oral metronidazole is first-line therapy for mild Clostridium difficile -associated diarrhea, while vancomycin should be reserved for severe CDAD. Major Points After the millennium it was unclear whether vancomycin or metronidazole should be preferred for first-line treatment of Clostridium difficile -associated diarrhea (...) medications Exclusion Criteria Suspected or proven life-threatening intraabdominal complications (eg, perforated viscus, bowel obstruction) Prior CDAD with failure to respond to either study drug Pregnancy History of allergy to either study drug Treatment with oral vancomycin or parenteral/oral metronidazole during prior 14 days Patients not allowed to receive antidiarrheal medications or drugs with potential activity against Clostridium difficile Baseline Characteristics Comparisons are mild vs. severe

2007 Wiki Journal Club

11464. Childhood Diarrhoea

Childhood Diarrhoea Childhood Diarrhoea. Kids Diarrhoea Treatment. Patient | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Childhood Diarrhoea Authored by , Reviewed by | Last edited 15 Dec 2014 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European (...) situation. Further investigations may include endomysial antibodies (coeliac disease), intestinal biopsy (coeliac disease or inflammatory bowel disease) and sweat test (cystic fibrosis) if indicated, especially if diarrhoea persists. Management See also separate and articles. Most infectious diarrhoea is self-limiting and medical care is mainly supportive. The important aspects of management are recognition of more serious causes of diarrhoea and adequate oral rehydration at an early stage. Infants

2008 Mentor

11465. Chronic Diarrhoea in Adults

/j.gastro.2009.02.072. Epub 2009 May 7. ; An instrument for the assessment of diarrhoeal severity based on a longitudinal community-based study. BMJ Open. 2014 Jun 64(6):e004816. doi: 10.1136/bmjopen-2014-004816. ; Evaluating the patient with diarrhea: a case-based approach. Mayo Clin Proc. 2012 Jun87(6):596-602. doi: 10.1016/j.mayocp.2012.02.015. ; NICE CKS, March 2013 (UK access only) ; Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2014 (...) Chronic Diarrhoea in Adults Chronic Diarrhoea in Adults. Free medical advise. Patient | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Chronic Diarrhoea in Adults Authored by , Reviewed by | Last edited 17 Dec 2014 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK

2008 Mentor

11466. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis

Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis Van Niel C W, Feudtner C, Garrison M M, Christakis D A Authors' objectives To determine whether treatment with Lactobacillus improves clinical outcomes in children with acute infectious diarrhoea. Searching MEDLINE, EMBASE, the Cochrane Controlled Trials (...) of children with infectious diarrhoea. Research: The authors recommended a large RCT, funded by a non-vested party, to test whether high-dose Lactobacillus is an effective treatment for infectious diarrhoea in ambulatory children. They also recommended the use of standardised measurements of diarrhoea intensity to aid interpretation of the results. Bibliographic details Van Niel C W, Feudtner C, Garrison M M, Christakis D A. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis

2002 DARE.

11467. Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn’s Disease

Information provided by: ChemoCentryx Study Details Study Description Go to Brief Summary: The purpose of this research study is to investigate the effects of an investigational medication, called CCX282-B, on safety and on the some of the symptoms of Crohn’s Disease in patients who are experiencing an active flare-up of moderate to severe Crohn’s Disease. Condition or disease Intervention/treatment Phase Crohn Disease Drug: CCX282-B Phase 2 Detailed Description: CCX282-B is being developed as a treatment (...) Events, tolerability) Secondary Outcome Measures : Inflammatory Bowel Disease Questionnaire C-reactive protein Endoscopic appearance and biopsy of colon and terminal ileum Markers of leukocyte subsets and activation status Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor

2005 Clinical Trials

11468. Comparison of Two Regimens of Misoprostol for Second Trimester Medical Termination of Pregnancy

: Nilratan Sircar Medical College Information provided by: Nilratan Sircar Medical College Study Details Study Description Go to Brief Summary: The hypothesis of the study is that the induction abortion interval time will be significantly shorter in the group receiving vaginal misoprostol every six hours in comparison to the group who are receiving vaginal misoprostol every twelve hours. Condition or disease Intervention/treatment Phase Induced Abortion Drug: Misoprostol Phase 4 Detailed Description (...) and symptoms severe enough to preclude the use of additional drugs. The patient's vital signs will be monitored every four hours and the occurrence of signs and symptoms, such as fever, pain, vomiting, and diarrhea will be recorded. After expulsion of the fetus and placenta, check curettage will be done in every case. Completeness of abortion will be defined as expulsion of both placenta and fetus without operative assistance. The induction abortion interval will be defined as time from administration

2006 Clinical Trials

11469. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. (Abstract)

A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. Medications often cause constipation and little data are available concerning treatment interventions. This study was designed to evaluate the safety and efficacy of polyethylene glycol (PEG) 3350 laxative (MiraLax) for relief of constipation from medicines associated with symptoms of constipation.Study subjects were enrolled who met defined criteria for chronic constipation (...) and were also taking medications that were associated with a reported side effect incidence of more than 3% constipation. Subjects were randomized into a double-blind, parallel, multicenter study where they received 17 g per day of PEG laxative or placebo for 28 days. The primary efficacy variable, "Treatment Success," was defined as relief of ROME II criteria for constipation over the last 7 days of the treatment period. Various secondary measures were also assessed. Daily bowel movement experience

2007 Southern medical journal Controlled trial quality: predicted high

11470. Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

Actual Study Completion Date : September 2007 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: A One pill of abacavir/lamivudine/zidovudine twice daily Drug: Abacavir sulfate, lamivudine, and zidovudine one pill twice daily Experimental: B One pill of zidovudine/lamivudine and four pills of lopinavir/ritonavir twice daily. Drug: Lamivudine/zidovudine one pill twice daily Drug: Lopinavir (...) /ritonavir four pills twice daily Outcome Measures Go to Primary Outcome Measures : Proportion of women in each treatment group with virologic suppression to less than 400 copies/ml at 34th week of pregnancy (or last viral load prior to delivery, if delivery occurs before 34th week of pregnancy) while continuing on assigned therapy [ Time Frame: at Week 34 of pregnancy ] Secondary Outcome Measures : Primary outcome, evaluating ART naive and ART experienced women [ Time Frame: throughout study ] HIV

2004 Clinical Trials

11471. Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

: December 2008 Actual Primary Completion Date : January 2012 Actual Study Completion Date : August 2012 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: CS-7017 with Paclitaxel and Carboplatin Drug: CS7017 tablets CS7017 tablets, strength 0.25mg, two tablets, two times daily for twenty-five to thirty months Drug: Paclitaxel IV, 200mg/m2, once every three weeks for up to 18 (...) weeks Drug: Carboplatin IV, AUC of 6, once every three weeks for up to 18 weeks Placebo Comparator: Paclitaxel and Carboplatin Drug: Paclitaxel IV, 200mg/m2, once every three weeks for up to 18 weeks Drug: Carboplatin IV, AUC of 6, once every three weeks for up to 18 weeks Drug: Placebo Tablets Placebo tablets matching CS-7017 tablets Outcome Measures Go to Primary Outcome Measures : Progression-free survival (PFS) rate [ Time Frame: week 18 ] Secondary Outcome Measures : Median Progression Free

2008 Clinical Trials

11472. The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients

criteria of the Alzheimer's Disease and Related Disorders Association Rated 1 and 2 (mild to moderate level) on the Brazilian version of the Clinical Dementia Rating Exclusion Criteria: Other causes of dementia Other severe medical or psychiatric disease Clinical indication of psychoactive drugs other than experimental drug Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using (...) : donepezil Drug: Placebo Phase 4 Detailed Description: Central acting cholinesterase inhibitors are the first primary pharmacological treatment approved for Alzheimer disease, of which donepezil is the most frequently used. Multicenter studies have found little toxicity, and its side effects (diarrhea, nausea, vomiting, nightmares, among others) are mild and transient. According to the literature, cholinergic active drugs may be expected to affect REM (rapid eye movement) sleep. Another possible effect

2007 Clinical Trials

11473. Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal

Medicine Collaborator: Cheikh Anta Diop University, Senegal Information provided by: London School of Hygiene and Tropical Medicine Study Details Study Description Go to Brief Summary: The purpose of this trial is to compare the acceptability, efficacy and safety of three alternative drug regimens for use for seasonal Intermittent Preventive Treatment to prevent malaria in children. Children aged 2 months to 5 years will be randomized to receive IPT with one of three regimens during the transmission (...) Actual Primary Completion Date : December 2007 Actual Study Completion Date : December 2007 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: 1 sulfalene pyrimethamine plus amodiaquine Drug: sulfalene-pyrimethamine plus amodiaquine Monthly treatments during the malaria transmission season Other Name: Dualkin Active Comparator: 2 dihydroartemisinin piperaquine Drug

2007 Clinical Trials

11474. An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

have not experienced significant blood level changes, e.g. very low platelets, while on previous bortezomib therapy Prior radiation therapy to > 25% of the bone marrow (whole pelvis is 25%). Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00555906 (...) An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study

2007 Clinical Trials

11475. Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children

will make home visits and phone calls to each patient's parent or guardian the first week of each treatment regimen. Medical history, documentation of direct observation of therapy (DOT), a physical exam, and urine collection will occur on Days 25 and 53. Also on Days 25 and 53, patients will be admitted to the hospital to ensure 100% medication adherence and to provide blood for PK studies. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual (...) Primary Completion Date : September 2008 Actual Study Completion Date : September 2008 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: A, Stage 1 Tablet containing d4T, 3TC, and NVP taken orally twice daily for the first 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for the final 4 weeks Drug: Lamivudine, nevirapine, and stavudine fixed-dose tablet 7 mg d4T

2006 Clinical Trials

11476. Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients

Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Outcome Measures Go to Primary Outcome Measures : Pharmacokinetic blood samples will be taken just before dosing Malarone, and 12 samples in the time between 0,5 hour and 168 hours after dosing. Secondary Outcome Measures : Blood will be taken for genotyping of CYP2C19 at study day 1. HIV-1 RNA and CD4 determination will be done (HIV patients only) at inclusion screening (...) and 30 kg/m2 able and willing to sign informed consent form use of lopinavir/ritonavir, atazanavir/ritonavir or efavirenz for at least 1 month in a dose of 400/100mg bid, 300/100 mg QD, or 600 mg QD respectively Exclusion Criteria healthy volunteers: History of sensitivity/idiosyncrasy to atovaquone/proguanil or chemically related compounds or excipients. Positive HIV test. Positive HbsAg test (hepatitis B) or positive hepatitis C test. Therapy with any drug (for two weeks preceding dosing), except

2007 Clinical Trials

11477. Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients

Any acute illness within 2 weeks prior to Day 0 Patients requiring the continued use of inhibitors or inducers of P450 metabolic enzymes Patients requiring systematic treatment with CYP3A4 substrates Patients with malabsorption, severe chronic diarrhea Receipt of any cytotoxic therapy for malignancy Current grade 3 or 4 clinical or laboratory toxicity Pregnancy or breast-feeding Females of childbearing potential not using adequate contraception. allergy or known drug hypersensitivity to any (...) in antiretroviral drug naive pediatric patients. Secondary objective: To assess efficacy and safety of nevirapine 150 mg/m2 and nevirapine 4/7mg/kg after 24 and 48 weeks of treatment Study Hypothesis: Evaluation of recent pharmacokinetic data has suggested that a dose based on body surface area rather than body weight might be a better therapeutic regimen to achieve steady state plasma concentrations. The goal in this study was to determine if a Nevirapine suspension dose of 150 mg/m2 BID, following a two week

2006 Clinical Trials

11478. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. (Abstract)

Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. The eradication rates of Helicobacter pylori with standard treatments are decreasing worldwide.The primary aim of this study was to compare the eradication success of a 14-day sequential regimen with proton pump inhibitor (PPI)-based triple treatment. The secondary objectives of the study were (...) and amoxicillin 1 g for 7 days, followed by pantoprazole 40 mg, tetracycline 500 mg, and metronidazole 500 mg for the next 7 days. The second group was administered pantoprazole 40 mg, amoxicillin 1 g, and clarithromycin 500 mg (PAC group) for 14 days. All drugs were administered BID, with the exception of tetracycline, which was administered QID. Eradication was confirmed by (14)C-UBT 6 weeks after the end of the treatment. Histologic examination and (14)C-UBT were conducted by investigators blinded

2008 Clinical therapeutics Controlled trial quality: uncertain

11479. FDA drug approval summaries: oxaliplatin. (Abstract)

FDA drug approval summaries: oxaliplatin. The purpose of this report is to summarize information on oxaliplatin, a drug recently approved by the U.S. Food and Drug Administration. Information provided includes regulatory history, study design, efficacy and safety results, and pertinent literature references. A single, multicenter, randomized trial, enrolling 463 patients with metastatic colorectal carcinoma whose disease had recurred or progressed during or within 6 months of completion (...) of therapy with the combination of bolus 5-fluorouracil (FU)/leucovorin (LV) and irinotecan, was submitted. Study arms included infusional 5-FU/LV alone (arm A), oxaliplatin alone (arm B), and the combination of oxaliplatin and infusional 5-FU/LV(arm C). Oxaliplatin, at a dose of 85 mg/m2, was administered to patients in arms B and C intravenously over 2 hours in 250-500 ml of dextrose 5% in water (D5W) on day 1 only. A 200-mg/m2 dose of LV was administered simultaneously to arm C patients, in a separate

2004 The oncologist Controlled trial quality: uncertain

11480. EPO906 Therapy in Patients With Advanced Kidney Cancer

Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Renal Cancer Study Start Date : April 2002 Actual Primary Completion Date : August 2003 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: EPO906 Drug: epothilone b EPO906 (...) or fistulae HIV+ patients Pregnant or lactating females. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00035243 Locations Layout table for location information United States, California UCLA Medical Center Los Angeles, California, United States, 90095

2002 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>